- Grant Applications
- Research News & Reports
- Research Webinar Series
- Clinical Trials
- HD Gene Symposium: 20 Years
- Therapies in Pipeline
- Research Conferences
- Scientific Advisory Board
- Research Pipeline
- Stem Cells
- Minocyline-the end of the road?
- Memantine in HD: dose is everything
- Active Lifestyle
- How Common is HD?
- PLoS Currents Huntington Disease
- Do HD Brains Develop Differently?
- Connections between Neurodegenerative diseases?
- Focused Drug Screening
- HDBuzz on KMO Inhibitor
- HDBUZZ: Digestive Problems in HD
- HDBuzz Re-routing huntingtin inside cells
- HDBuzz Making Babies
- HDBuzz: Caffeine, cannabis and caution
- HDBuzz Cut-and-paste DNA
- Stem cells and HD: past, present and future
- HDBuzz Hidden message in HD gene?
- HDBuzz Protein folding drug helps mice . . . for a while
- Oz Buzz Updates: Day 1
- Oz Buzz Updates: Day 2
- Oz Buzz Updates: Day 3
- Prana Biotech PBT2 Clinical Trial
- Gene Silencing Takes a Targeted Step Forward
- TRACK-HD reveals changes in HD mutation carriers
- HD Buzz: Chinese HD Network
- HDBuzz: Gene Therapy and Stem Cells
- HDBuzz: Bone marrow transplantation in HD
- Double success for huntingtin RNAi gene silencing
- HDBuzz: Mesenchymal stem cells and gene silencing
- HDBuzz: Special 'brain fat' injection helps HD mice
- HDBuzz: Mutant yeast highlights crucial CAG-reading protein
- HDBuzz: New analysis suggests 'small' CAG length doesn't matter at all
- HDBuzz Gray Area of HD
- HDBuzz Exosomoes
- HDBuzz Neutron Ray
- Sheep Brains and HD
- HDBuzz: Stem-cell neurons make the right connections
- HDBuzz: Closing the care gap new guidelines for HD care
- HDBuzz: What's the connection between Huntington's and cancer?
- HDBuzz: ASO gene silencing reaches further, lasts longer
- HDBuzz: Induced stemm cells make exciting advances
- Mapping the neighborhood: huntingtin's new protein partners
- HDBuzz: Does the HD Mutation affect Children's Growth
- HDBuzz Lithium with a twist gets second chance for HD
- HDBuzz: High-power brain scans reveal sodium changes in HD
- HDBuzz: Single Stranded RNA gene silencing
- CHDI Conference- Day 1
- CHDI Conference- Day 2
- HD Buzz on CHDI Conference- Day 3
- HDBuzz: Illuminating Findings in Blood Cells
- Targeting oxidative stress in Huntington's Disease
- HDBuzz: Guard Dog Proteins
- HDBuzz: Dyeing to prevent dying?
- HDBuzz: Prominent HD researcher fabricated data
- HDBUZZ: Prana Biotech Publishes Animal Data
- HDBuzz: Gone fishing: protein network screen
- UNO has not discovered a cure for HD
- HDBuzz: HD and Sleep
- HDBuzz: N17 Region of Huntingtin
- HDBuzz: Liver changes in Huntington Patients
- HDBuzz: No Surprises in Published HART results
- HDBuzz: New Genetic Testing Technique
- HDBuzz: Rules for a good Sleep
- HDBuzz: Lost in translation?
- HDBuzz: Major Roche-Isis deal
- HDBuzz: Is Access to Genetic Testing a Problem?
- HDBuzz: Splicing with Danger
- HDBuzz: Landmark Study puts HD trials on TRACK
- HD Glossary
- Links to Other Research
- Past & Future
- HD Insights
- Reports Library
What's the connection between Huntington's Disease and cancer?
HD patients are less likely to get cancer, according to a study from Sweden - what does this mean?
By Dr Jeff Carroll on April 25, 2012
Edited by Dr Ed Wild
Amongst the general population, cancer is one of the most feared killers. HD families might be forgiven for not thinking much about cancer, given the more obvious clear and present danger. But it turns out that there might be a connection between the mutation that causes HD and the risk of developing cancer, which could help us understand both conditions.
History of HD and cancer
In 1999, Dr. Jørgen Olsen and colleagues published a paper that suggested that cancer incidence was lower in people carrying an HD mutation than their at-risk relatives. In fact, the risk of cancer in HD patients was strikingly lower, by about 40%.
If true, this is a dramatic result — anyone developing a cancer drug would be elated with a 40% reduction in tumors. Even more striking — people carrying the HD mutation didn’t just have less of one specific type of cancer, but a broad array of tumor types.
This finding has been much discussed amongst HD researchers, but until recently hadn’t been replicated in another study. Replication is when a claim made by one researcher is tested again, and found to be valid by an independent group. It’s a critical part of science. Scientists are a naturally skeptical group, and it helps convince them when more than one group sees the same thing.
The importance of databases
A new study, from Jan Sundquist and colleagues from Lund, Sweden, has just been reported in the journal Lancet Oncology. This study took advantage of three large registries of patients in Sweden — the ‘Swedish Hospital Discharge Register’, the ‘Outpatient Registry’ and the ‘Swedish Cancer Registry’.
These large databases collect information on nearly all patients in Swedish hospitals, which enable a much more through collection of information than a person-by-person collection of data. In fact, the investigators were able to collect information going as far back as 1969 — nearly 4 decades of data on patients in Swedish hospitals.
Not just HD
The researchers were curious, not just about HD, but about all diseases caused by a similar mutation. HD is the result of a very specific genetic stutter — the genetic sequence C-A-G is repeated a number of times in the gene we call huntingtin.
While HD is always caused by this stutter in the huntingtin gene, other diseases are caused by a similar mutation — a prolonged repetition of the genetic sequence C-A-G — in different genes. At least 14 distinct human diseases are by C-A-G mutations in various genes.
In the recent cancer study, researchers looked at people with Huntington’s disease, as well as two other ‘CAG repeat’ diseases — spinobulbar muscular atrophy (SBMA) and spinocerebellar ataxia (SCA), both of which cause neurological problems. All three diseases are caused by genetic stutters that increase CAG sizes in different genes.
Looking back over many years of data, the researchers found 1,510 cases of HD, 471 cases of SBMA and 3,425 cases of SCA. For quite rare diseases, having a study population of over 5,000 patients is extraordinary.
Cross-referencing the cancer database revealed a surprising fact — all the mutation carriers examined had a lower incidence of cancer.
When physicians and scientists talk about the risk of inheriting a disease, they often use the term odds ratio. An odds ratio compares the chance of something happening in one group to the chance of it happening in the general population.
An odds ratio of 1.0 means there’s no difference between your subjects and the control population — they have the same risk. An odds ratio of greater than 1.0 suggests that your subjects are more likely to experience a disease.
With cancer and the CAG-repeat diseases, researchers found an overall odds ratio of between 0.4-0.7, depending on the mutation and tumor type studied. This is remarkable: it means that patients carrying a CAG-expanded gene are about half as likely to have cancer as people who don’t carry the mutation.
Lifespan and other controls
Of course, the whole problem with CAG-expansions is that people who have them don’t live as long as people who don’t. Could this explain the apparent lack of cancer?
Researchers mathematically corrected for this type of problem. Essentially, they asked the question: “for every year a person is alive, how likely are they to develop cancer?” When looked at this way, the protection was still there — suggesting that it’s not simply early death in mutation carriers, but that they really are really protected from tumors.
What if it’s something in the environment of people with CAG-repeat disease that makes them less susceptible to cancer? We could easily confuse some environmental effect, like a different kind of diet, with a more interesting one.
The researchers considered this question by comparing CAG-expansion patients to a parent who didn’t carry a CAG-expansion mutation. This is a nice way of controlling for environment because people share environments with their parents for a long time.
In fact, the results were the same when this type of analysis was done. The parents of CAG-expansion disease patients who didn’t carry the mutation have the same rate of cancer as the general population.
Other, more sophisticated, kinds of corrections were also done to look for confounding factors. The researchers considered the era people lived in, the type of job they did, their gender and other things that could confound their result. After controlling for all these different factors, the impact of carrying a CAG-expansion mutation was still there — it seems very real.
Implications and questions
Clearly, no one is going to seek out a CAG-expansion mutation to protect themselves from cancer. So why do we care about this kind of observational study?
This type of research helps us learn about the basic biology of both CAG-expansion diseases and cancer. It now seems clear that people carrying one of these mutations — in any gene — have a difference in the ways their cells or tissues works that makes them less susceptible to a broad array of types of cancer. This means there’s some really important commonality in the way these mutations change the function of their host gene, and argues for continued study of all CAG-expansion diseases, not just HD.
It also hints at one aspect of HD that has mystified researchers since the mutation was found — why does the huntingtin gene tend to grow, when the result of that expansion is as harmful as HD? Finding beneficial effects like this helps us understand that there might be a balance at work — bigger CAG sizes might be good for some things, but put us at higher risk for HD and other diseases.
Unraveling the details of this could provide very exciting understanding about the obscure biology of the genes that cause CAG-expansion diseases, as well as how cancer develops in people.
Link to original paper describing reduced cancer in HD patients (full article requires payment or subscription)
Earlier study suggesting that cancer incidence is lower in HD patients (full article requires payment or subscription)
HD just got cilia
Huntexil update: EMA asks for further trial
Improving Huntington's disease clinical trial recruitment through patient and family education
The genetic 'gray area' of Huntington's disease: what does it all mean?